Distributor inventory | Tablet
Sitagliptin 100 mg + Dapagliflozin 10 mg
Type 2 diabetes mellitus (as an adjunct to diet and exercise) to improve glycaemic control when dual therapy with a DPP-4 inhibitor and an SGLT2 inhibitor is appropriate.
Sitagliptin (DPP-4 inhibitor) increases incretin levels, leading to glucose-dependent increase in insulin release and reduced glucagon secretion. Dapagliflozin (SGLT2 inhibitor) reduces glucose reabsorption in the kidneys, increasing urinary glucose excretion and lowering blood sugar.
Take orally exactly as prescribed by the doctor, usually once daily, with or without food. Swallow whole with water; take at the same time each day. Maintain adequate hydration; do not stop or change dose without medical advice.
Common side effects of SITANOON-D 100/10MG TAB may include:
For type 2 diabetes only (not for type 1 diabetes). Risk of diabetic ketoacidosis (may occur even with near-normal glucose) with SGLT2 inhibitors—seek urgent care for nausea, vomiting, abdominal pain, rapid breathing. May cause dehydration/low blood pressure; use caution in elderly and with diuretics. Monitor kidney function; not recommended in severe renal impairment or dialysis (dapagliflozin effectiveness reduced and risk increases). Increased risk of genital/urinary infections; maintain hygiene and report symptoms. Temporarily stop before major surgery or during acute illness/fasting as advised. Use caution in history of pancreatitis (sitagliptin) and severe hypersensitivity reactions.
